---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-027394"
form_type: "8-K"
ticker: null
cik: "0001808158"
company_name: "Repare Therapeutics Inc."
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T07:05:31.786107+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Repare Therapeutics acquired by XenoTherapeutics for ~$2.20/sh plus CVR

## Summary
- Completion of acquisition by XenoTherapeutics; shareholders received ~$2.20 per share in cash plus one CVR per share.
- Transaction approved by shareholders on Jan 16, 2026; court order obtained Jan 23, 2026.
- Common shares to cease trading on Nasdaq on/about Jan 28, 2026; Form 15 to be filed to suspend reporting obligations.
- All directors resigned; Jon Adkins (sole director of Purchaser) becomes sole director and officer of surviving corporation.
- Contingent value rights (CVR) represent right to receive pro rata portion of potential future cash payments.

## SEC filing metadata
- accession: 0001193125-26-027394
- form_type: 8-K
- cik: 0001808158
- company_name: Repare Therapeutics Inc.
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808158/000119312526027394/0001193125-26-027394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808158/000119312526027394/d95398d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-027394
- JSON: https://secwatch.observer/filing/0001193125-26-027394.json
- Plain text: https://secwatch.observer/filing/0001193125-26-027394.txt

## Source-grounded claims
- claim_id: 5c64375fb517c5c061b2131113c9f572f3fea362
  claim: Repare Therapeutics Inc. underwent a change of control involving XenoTherapeutics, Inc. and Xeno Acquisition Corp. for approximately US$2.20 per Common Share (closed 2026-01-28).
  evidence_excerpt: by reference herein. Subject to the terms and conditions set forth in the Agreement, on January 28, 2026, the Shareholders received a cash payment of approximately US$2.20 per Common that was determined based upon the Company’s cash balance immediately prior to the closing of the Transaction (the “Closing”) after deducting certain transaction costs,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808158/000119312526027394/0001193125-26-027394-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.